Avita Medical | 1811094D - 销售收入

股票价格
1.22
每天变化
-0.04 -2.80%
每月一次
13.02%
每年
-59.90%
Q2 预测
1.22


金融业
股票价格
AUD
资产
AUD 56.39M
现金及等价物
AUD 10.24M
销售成本
AUD 3.3M
流动资产
AUD 35.49M
流动负债
AUD 62.68M
债务
AUD 46.05M
EBIT
AUD -10.39M
EBITDA
AUD -9.69M
员工
AUD 87
EPS每股收益
AUD -0.38
股本和储备
AUD -16.65M
销售毛利
AUD 14.31M
债务利息支出
AUD 1.25M
贷款资金
AUD 42.25M
市值
AUD 159.33M
净收入
AUD -11.62M
营业费用
AUD 28.02M
营业利润
AUD -10.41M
税前利润
AUD -11.64M
销售收入
AUD 17.62M
销售和管理费用
AUD 19.03M
股票
AUD 6.93M
贸易债权人
AUD 8.96M
应收帐款人
AUD 9.11M


销售 更改 日
Accuray USD 116.17M 14.63M 2024-12
Celltrion KRW 1.33T 0 2026-03
Clinuvel Pharmaceuticals AUD 36.93M 22.44M 2025-12
Cochlear AUD 1.18B 590.35M 2025-12
CSL USD 8.33B 4.79B 2025-12
Cspc Pharmaceutical CNY 6.11B 502.75M 2025-12
Deva Holding AS TRY 2.32B 418.58M 2023-09
Dianthus Therapeutics USD 284K 112K 2025-12
Divis Laboratories Ltd INR 26.04B 1.11B 2025-12
Kangmei Pharma CNY 1.37B 101.16M 2025-09
Knight Therapeutics CAD 133.11M 11.56M 2025-12
Laboratorios Farma EUR 448.66M 67.82M 2023-12
Mayne Pharma AUD 212.07M 17.03M 2025-12
Medical Developments International AUD 21.57M 12.04M 2025-12
Nanosonics AUD 102.23M 2.8M 2025-12
Neuren Pharmaceuticals AUD 42.24M 28.1M 2025-12
Organigram Holdings CAD 63.54M 16.52M 2025-12
Pacific Edge NZD 5.94M 4.95M 2025-12
Paradigm Biopharmaceuticals AUD 284.06K 292.06K 2025-12
Pharma Mar EUR 90.2M 54.5M 2025-12
Polynovo AUD 70.33M 35.75M 2025-12
PYC Therapeutics AUD 11.04M 2.44M 2025-12
Qiagen NV USD 419.22M 38.16M 2026-03
Ramsay Health Care AUD 9.34B 82.2M 2025-12
ResMed USD 1.42B 87.23M 2025-12
Sartorius EUR 899.1M 28.5M 2026-03
Sino Biopharmaceutical CNY 14.26B 3.31B 2025-12
Telix Pharmaceuticals AUD 413.44M 103.71M 2025-12
Tilray USD 217.51M 74.75M 2025-12
Zealand Pharma A/S 68.91M 19.35M 2025-12
Zhangzhou Pientzehuang Pharmaceutical CNY 2.88B 642.99M 2025-09